|
1
|
Smith MA, Ries LA, Gurney JG, et al:
Leukemia. Cancer incidence and survival among children and
adolescents United States SEER Program 1975–1995. National Cancer
Institute, SEER Program; Bethesda, MD: pp. 17–34. 1999
|
|
2
|
Cantu-Rajnoldi A, Biondi A, Jankovic M, et
al: Diagnosis and incidence of acute promyelocytic leukemia (FAB M3
and M3 variant) in childhood. Blood. 81:2209–2210. 1993.PubMed/NCBI
|
|
3
|
Catovsky D, Matutes E, Buccheri V, et al:
A classification of acute leukaemia for the 1990s. Ann Hematol.
62:16–21. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Thé H and Chen Z: Acute promyelocytic
leukaemia: novel insights into the mechanisms of cure. Nat Rev
Cancer. 10:775–783. 2010.PubMed/NCBI
|
|
5
|
Lo-Coco F and Ammatuna E: The biology of
acute promyelocytic leukemia and its impact on diagnosis and
treatment. Hematology Am Soc Hematol Educ Program. 514:156–161.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Avvisati G, Petti MC, Lo-Coco F, et al:
Induction therapy with idarubicin alone significantly influences
event-free survival duration in patients with newly diagnosed
hypergranular acute promyelocytic leukemia: final results of the
GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up.
Blood. 100:3141–3146. 2002.
|
|
7
|
Mann G, Reinhardt D, Ritter J, et al:
Treatment with all-trans retinoic acid in acute promyelocytic
leukemia reduces early deaths in children. Ann Hematol. 80:417–422.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Botton S, Coiteux V, Chevret S, et al:
Outcome of childhood acute promyelocytic leukemia with
all-trans-retinoic acid and chemotherapy. J Clin Oncol.
22:1404–1412. 2004.PubMed/NCBI
|
|
9
|
Testi AM, Biondi A, Lo Coco F, et al:
GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed
acute promyelocytic leukemia (APL) in children. Blood. 106:447–453.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ortega JJ, Madero L, Martin G, et al:
Treatment with all-trans retinoic acid and anthracycline
monochemotherapy for children with acute promyelocytic leukemia: a
multicenter study by the PETHEMA Group. J Clin Oncol. 23:7632–7640.
2005. View Article : Google Scholar
|
|
11
|
Powell B, Moser B, Stock W, et al:
Preliminary results from the North American acute promyelocytic
leukemia (APL) study C9710 (abstract). Blood. 108:5662006.
|
|
12
|
Luo XQ, Ke ZY, Huang LB, et al: Improved
outcome for Chinese children with acute promyelocytic leukemia: a
comparison of two protocols. Pediatr Blood Cancer. 53:325–328.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gregory J, Kim H, Alonzo T, et al:
Treatment of children with acute promyelocytic leukemia: results of
the first North American Intergroup trial INT0129. Pediatr Blood
Cancer. 53:1005–1010. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jeddi R, Ghedira H, Ben Abdennebi Y, et
al: ATRA and anthracycline-based chemotherapy in the treatment of
childhood acute promyelocytic leukemia (APL): a 10-year experience
in Tunisia. Med Oncol. 28:1618–1623. 2010.PubMed/NCBI
|
|
15
|
Creutzig U, Zimmermann M, Dworzak M, et
al: Favourable outcome of patients with childhood acute
promyelocytic leukaemia after treatment with reduced cumulative
anthracycline doses. Br J Haematol. 149:399–409. 2010. View Article : Google Scholar
|
|
16
|
Imaizumi M, Tawa A, Hanada R, et al:
Prospective study of a therapeutic regimen with all-trans
retinoic acid and anthracyclines in combination of cytarabine in
children with acute promyelocytic leukaemia: the Japanese childhood
acute myeloid leukaemia cooperative study. Br J Haematol.
152:89–98. 2011.PubMed/NCBI
|
|
17
|
Kim MHCC, Lee JW, Jang PS, et al: Outcome
of childhood acute promyelocytic leukemia treated using a modified
AIDA protocol. Korean J Hematol. 45:236–241. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ribeiro RC and Rego E: Management of APL
in developing countries: epidemiology, challenges and opportunities
for international collaboration. Hematology Am Soc Hematol Educ
Program. 2006:162–168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yeh TC, Liu HC, Wang LY, et al: The
development of a novel protocol for the treatment of de novo
childhood acute myeloid leukemia in a single institution in Taiwan.
J Pediatr Hematol Oncol. 29:826–831. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang L, Zhao H, Zhu X, et al:
Retrospective analysis of 65 Chinese children with acute
promyelocytic leukemia: a single center experience. Pediatr Blood
Cancer. 51:210–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Avvisati G, Lo Coco F, Diverio D, et al:
AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed
acute promyelocytic leukemia: a Gruppo Italiano Malattie
Ematologiche Maligne dell’Adulto (GIMEMA) pilot study. Blood.
88:1390–1398. 1996.
|
|
22
|
De Botton S, Chevret S, Coiteux V, et al:
Early onset of chemotherapy can reduce the incidence of ATRA
syndrome in newly diagnosed acute promyelocytic leukemia (APL) with
low white blood cell counts: results from APL 93 trial. Leukemia.
17:339–342. 2003.PubMed/NCBI
|
|
23
|
Cheson BD, Cassileth PA, Head DR, et al:
Report of the National Cancer Institute-sponsored workshop on
definitions of diagnosis and response in acute myeloid leukemia. J
Clin Oncol. 8:813–819. 1990.PubMed/NCBI
|
|
24
|
Sanz MA, Lo Coco F, Martin G, et al:
Definition of relapse risk and role of nonanthracycline drugs for
consolidation in patients with acute promyelocytic leukemia: a
joint study of the PETHEMA and GIMEMA cooperative groups. Blood.
96:1247–1253. 2000.PubMed/NCBI
|
|
25
|
Huang S, Guo A, Xiang Y, et al: Clinical
study on the treatment of acute promyelocytic leukemia with
composite Indigo Naturalis tablets. Chin J Hematol. 16:26–28.
1995.
|
|
26
|
The cooperation group phase II: Clinical
trial of compound Huangdai tablet in newly diagnosed acute
promyelocytic leukemia. Chin J Hematol. 12:801–804. 2006.
|
|
27
|
Wang L, Zhou GB, Liu P, et al: Dissection
of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis
as an effective treatment for promyelocytic leukemia. Proc Natl
Acad Sci USA. 105:4826–4831. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xiang Y: The influence on long-term survey
of the patients with acute promyelocytic leukemia treated with
compound Huangdai tablets and chemotherapy. Chin J Clin Hematol.
16:204–206. 2007.
|
|
29
|
Rizzari C and Biondi A: Tailoring
treatment strategy for acute promyelocytic leukemia in low-income
countries. Pediatr Blood Cancer. 53:303–305. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Preisler H, Davis RB, Kirshner J, et al:
Comparison of three remission induction regimens and two
postinduction strategies for the treatment of acute nonlymphocytic
leukemia: a cancer and leukemia group B study. Blood. 69:1441–1449.
1987.
|
|
31
|
Dillman RO, Davis RB, Green MR, et al: A
comparative study of two different doses of cytarabine for acute
myeloid leukemia: a phase III trial of Cancer and Leukemia Group B.
Blood. 78:2520–2626. 1991.PubMed/NCBI
|
|
32
|
Schiller G, Gajewski J, Nimer S, et al: A
randomized study of intermediate versus conventional-dose
cytarabine as intensive induction for acute myelogenous leukaemia.
Br J Haematol. 81:170–177. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weick JK, Kopecky KJ, Appelbaum FR, et al:
A randomized investigation of high-dose versus standard-dose
cytosine arabinoside with daunorubicin in patients with previously
untreated acute myeloid leukemia: a Southwest Oncology Group study.
Blood. 88:2841–2851. 1996.
|
|
34
|
Mayer RJ, Davis RB, Schiffer CA, et al:
Intensive postremission chemotherapy in adults with acute myeloid
leukemia. Cancer and Leukemia Group B. N Engl J Med. 331:896–903.
1994. View Article : Google Scholar : PubMed/NCBI
|
